NCT00154232View on ClinicalTrials.gov

Study to Evaluate the Combination of Enteric-coated Mycophenolate Sodium (EC-MPS), Basiliximab, and C2-monitored Cyclosporine in de Novo Renal Transplant Recipients at Potential High Risk of Delayed Graft Function (DGF)

PHASE4CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

March 31, 2005

Conditions
Renal Transplantation
Interventions
DRUG

Enteric-Coated Mycophenolate Sodium (EC-MPS)

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY